Articles from GOA Therapeutics Corporation

New preclinical findings advance GOA26’s goal of reducing alcohol-related risks during anesthesia and emergency surgery

Eligible investors can now participate in the development of GOA26, designed to rapidly lower blood alcohol concentration and sequester acetaldehyde

Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning

In a porcine model of severe acute alcohol intoxication, GOA26 demonstrated a rapid reduction in blood alcohol concentration and multi-system biochemical recovery across metabolic, muscle, hematological and liver biomarkers.

Financing strategy designed to support GOA26 through clinical development, manufacturing, regulatory activities and commercialization planning

Company presented IND-enabling preclinical data earlier today at the AAST annual meeting